Device Trial Radar · NCT02482766
Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With RDS
Last checked: Nov 20, 2026Latest source record: Feb 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
206
Actual
Start
Nov 2015
Primary completion
Sep 2018
Study completion Sep 30, 2018
Sponsor
- Lead sponsor
- Catholic University of the Sacred HeartAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ospedali Riuniti Ancona; Careggi Hospital; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Centre for Neonatal Research and Education, Crawley, West Australia; Monash University; Azienda Ospedaliera San Gerardo di Monza; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- First posted
- Jun 26, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 24 weeks, up to 27 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary hypothesis of this study is reduction in need of mechanical ventilation in the first 72 hours of life (excluding the transient tracheal intubation performed for surfactant administration and the mechanical ventilation for lung recruitment) in spontaneously breathing infants born at 24+0-27+6 weeks' gestation and failing nCPAP during the first 24 hours of life who received an HFOV recruitment maneuver (IN-REC-SUR-E) compared to no recruitment maneuver (IN-SUR-E) just prior to surfactant administration followed by prompt extubation.
Conditions
- Respiratory Distress Syndrome
- Hyaline Membrane Disease
Interventions
Poractant alfa, 200 mg/kgDrug
Endotracheal Surfactant administration
Ventilator for High-frequency Oscillatory Ventilation (HFOV)Device
This device will be used to perform an HFOV recruitment maneuver before surfactant administration
Nasal Continuous Positive Airway Pressure (nCPAP)Device
After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Need for mechanical ventilation within the first 3 days of life and therefore we consider IN-REC-SUR-E a success if mechanical ventilation is not required and a failure if the infant needs mechanical ventilation in the first 72 hours.Time frame: First 72 hours of life
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
SS Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
Azienda Ospedaliera Universitaria Ferrara
Ferrara, Italy
Careggi
Florence, Italy
30 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.